InvestorLens

NVO — NOVO-NORDISK A S

Health Care · Drug Manufacturers

Sign in to save4 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying NVO?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
95
Institutional Conviction
Strong distribution · 0 buying vs 1 selling last quarter
8
Macro Tailwind
Macro conditions are mixed for this sector
53
Congressional Activity
1 congressional purchase, 0 sales disclosed in the last 6 months
Why? — Evidence & Confidence ▾

Of 1 tracked investors who changed their NVO position last quarter, 0 bought and 1 sold (0% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 53/100 in a Overheat regime). 1 congressional purchase, 0 sales disclosed in the last 6 months.

Supporting evidence
  • +4 tracked investors reported holding NVO at their latest filing
Contradicting evidence — always shown
  • −1 tracked investor reduced or exited last quarter (0 reduced, 1 sold out)
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/18/2026.

About NOVO-NORDISK A S (NVO)

NOVO-NORDISK A S (NVO) appears in the most recent 13F filings of 4 tracked institutional investors. NOVO-NORDISK A S is classified in the Health Care sector (Drug Manufacturers industry). The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $1.6B. Across recent filings, tracked investors recorded 5 new positions, 2 increased, 5 reduced, and 5 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in NVO

41
/100
Mixed Activity
Added / Increased7
Reduced5
Exited5
BearishBullish
Crowded Trade Score™

How many top investors track NVO

27
/100
Emerging Interest
4investors

A small number of top investors own this.

UndiscoveredCrowded
151015+

NVO Ownership Composition

How NOVO-NORDISK A S is held across tracked investor types, based on reported 13F positions.

Dominant Type
Multi-Strategy / Quant
96% of tracked value
Institutions
4
tracked investors
Total Reported
$1.4B
combined 13F value
Types2
  • Multi-Strategy / Quant95.8%
  • Macro4.2%
Multi-Strategy / Quant(3)
95.8%
Macro(1)
4.2%

Tracked investors currently reporting NVO

3 tracked investors have since exited this position — listed separately below.

  • Ken GriffinJun 30, 2026
    Citadel Advisors
    Shares
    19.3M
    Value
    $923.2M
    % Portfolio
    0.11%
  • Izzy EnglanderJun 30, 2026
    Millennium Management
    Shares
    5M
    Value
    $240.9M
    % Portfolio
    0.09%
  • Steve CohenJun 30, 2026
    Point72 Asset Management
    Shares
    3.6M
    Value
    $174.3M
    % Portfolio
    0.19%
  • Paul Tudor JonesJun 30, 2026
    Tudor Investment Corp
    Shares
    1.2M
    Value
    $58.9M
    % Portfolio
    0.08%

Previously held NVO

These investors reported NVO in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.

InvestorFirmLast reported sharesValue thenLast held
Chase ColemanTiger Global Management1.3M$87.6MJun 30, 2025
Philippe LaffontCoatue Management326.4K$38.9MSep 30, 2024
Ray DalioBridgewater Associates138.9K$7.7MSep 30, 2025

Recent activity

Frequently asked questions

How many institutional investors hold NVO?
4 tracked institutional investors disclosed a position in NVO (NOVO-NORDISK A S) in their most recent 13F filing.
Who is the largest institutional holder of NVO?
Ken Griffin, Citadel Advisors, holds the largest disclosed position in NVO, valued at $1.6B.
Did institutional ownership of NVO increase or decrease?
Across recent 13F filings, tracked investors recorded 5 new positions, 2 increased, 5 reduced, and 5 fully exited NVO.
What sector is NVO in?
NOVO-NORDISK A S is classified in the Health Care GICS sector, Drug Manufacturers industry.
Where does this NVO ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.
NVO (NOVO-NORDISK A S) — Institutional Holders & 13F History — InvestorLens